Skip to main content

Advertisement

Table 3 Cox regression predicting mortality risk for Women With Stage IV Breast Cancer (univariable and multivariable)

From: Could local surgery improve survival in de novo stage IV breast cancer?

Characteristic Univariable HR*(95%CI) P Multivariable HR*(95%CI) P
Surgery
 Yes vs No 0.56(0.382-0.820) 0.003 0.53(0.36-0.78) 0.001
Viscera metastasis
 Yes vs no 1.73 (1.18-2.54) 0.005  
Bone metastasis
 Yes vs no 0.91 (0.62-1.32) 0.610  
CNS metastasis
 Yes vs no 1.40 (0.44-4.43) 0.566  
Soft tissue metastasis
 Yes vs no 0.99 (0.68-1.46) 0.977  
Age
 ≤50 vs >50 0.65 (0.44-0.95) 0.026  
Menopause status
 Menopause vs menses 1.21 (0.82-1.77) 0.344  
Biopsy
 mass resection 0.753  
 core needle 1.32 (0.64-2.73) 0.457  
 fine needle 1.43 (0.18-11.59) 0.736  
Histology
 ductal 0.824  
 lobular 0.66 (0.16-2.69) 0.563  
 others 1.11 (0.41-3.05) 0.835  
Tumor size
 >5 cm vs ≤5 cm 1.00 (0.67-1.49) 0.981  
Lymph node involvement
 N0 0.259  
 N1 2.48 (1.00-6.11) 0.049  
 N2 1.95 (0.80-4.74) 0.142  
 N3 2.14 (0.91-5.05) 0.081  
HER2 receptor status
 Amplified 0.557  
 No-amplified 0.81 (0.55-1.21) 0.304  
 Not known or equivocal(2+) 0.77 (0.31-1.93) 0.574  
Hormone receptor status
 + vs - 0.49 (0.321-0.7233) <0.001 0.57 (0.36-0.89) 0.013
No. of metastasis sites
 >3 vs ≤3 1.751 (0.881-3.477) 0.11  
Endocrine therapy$
 Yes vs no 0.45 (0.30-0.68) <0.001 0.55 (0.35-0.86) 0.009
Anti-HER2 therapy$
 No 0.11  
 Yes 0.54 (0.325-1.008) 0.035  
 Unknown 0.00 (0.00-5.357E+159) 0.959  
Radiotherapy
 No 0.029  
 Yes 0.61 (0.40-0.94) 0.025  
 Unknown 1.35 (0.71-2.57) 0.357  
  1. Abbreviation: § Reference; * OFS = ovarian function suppression; CNS = central nervous system; HR = Hazard ratio; $Endocrine therapy were subsequent to chemotherapy; anti-HER2 therapy were incorporated into or subsequent to chemotherapy
  2. P values in bold italic are considered statistically significant